| Dr Casey C Bachison, MD | |
|
4403 Harrison Blvd, Suite 2400, Ogden, UT 84403-3271 | |
| (801) 387-2750 | |
| (801) 387-2755 |
| Full Name | Dr Casey C Bachison |
|---|---|
| Gender | Male |
| Speciality | Orthopedic Surgery |
| Experience | 19 Years |
| Location | 4403 Harrison Blvd, Ogden, Utah |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1235349820 | NPI | - | NPPES |
| 1235349820 | Medicaid | UT |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207X00000X | Orthopaedic Surgery | 4301088176 (Michigan) | Secondary |
| 207X00000X | Orthopaedic Surgery | 7989266-1205 (Utah) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Intermountain Homecare Ogden | Ogden, UT | Home health agency |
| Intermountain Homecare Home Health Logan | Logan, UT | Home health agency |
| Mckay Dee Hospital | Ogden, UT | Hospital |
| Davis Hospital And Medical Center | Layton, UT | Hospital |
| Layton Hospital | Layton, UT | Hospital |
| Logan Regional Hospital | Logan, UT | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Intermountain Healthcare Services, Inc | 1850209420 | 3063 |
News Archive
New research out of the University of Minnesota identifies significant risk factors for suicidal behavior in youth being bullied, but also identifies protective factors for the same group of children.
A platform that simulates how the body defends itself: The T cells of the immune system decide whether to trigger an immune response against foreign substances.
Mersana Therapeutics, a platform-based cancer therapeutics company, announced today positive preclinical pharmacokinetic data for its lead development candidate, XMT-1001, which is currently in a Phase 1 clinical trial in patients with advanced solid tumors. The results were presented in a poster session at the AACR 101st Annual Meeting 2010 in Washington, DC, held April 17-21, 2010.
Geron Corporation today announced enrollment of the first patient in a randomized Phase 2 clinical trial of its telomerase inhibitor drug, imetelstat (GRN163L), as maintenance therapy following platinum-based induction therapy for patients with non-small cell lung cancer (NSCLC).
Genomic Health, Inc. today announced results from a study demonstrating the critical role of manual microdissection to remove all biopsy cavities from breast cancer specimens. Genomic Health's Oncotype DX is the only commercially available breast cancer test that employs manual microdissection following review by a board certified surgical pathologist with breast expertise to predict a patient's benefit from chemotherapy and risk of disease recurrence.
› Verified 6 days ago
| Entity Name | Ihc Health Services Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1942325154 PECOS PAC ID: 1850209420 Enrollment ID: O20080610000303 |
News Archive
New research out of the University of Minnesota identifies significant risk factors for suicidal behavior in youth being bullied, but also identifies protective factors for the same group of children.
A platform that simulates how the body defends itself: The T cells of the immune system decide whether to trigger an immune response against foreign substances.
Mersana Therapeutics, a platform-based cancer therapeutics company, announced today positive preclinical pharmacokinetic data for its lead development candidate, XMT-1001, which is currently in a Phase 1 clinical trial in patients with advanced solid tumors. The results were presented in a poster session at the AACR 101st Annual Meeting 2010 in Washington, DC, held April 17-21, 2010.
Geron Corporation today announced enrollment of the first patient in a randomized Phase 2 clinical trial of its telomerase inhibitor drug, imetelstat (GRN163L), as maintenance therapy following platinum-based induction therapy for patients with non-small cell lung cancer (NSCLC).
Genomic Health, Inc. today announced results from a study demonstrating the critical role of manual microdissection to remove all biopsy cavities from breast cancer specimens. Genomic Health's Oncotype DX is the only commercially available breast cancer test that employs manual microdissection following review by a board certified surgical pathologist with breast expertise to predict a patient's benefit from chemotherapy and risk of disease recurrence.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Casey C Bachison, MD Po Box 27128, Salt Lake City, UT 84127-0128 Ph: (801) 387-2750 | Dr Casey C Bachison, MD 4403 Harrison Blvd, Suite 2400, Ogden, UT 84403-3271 Ph: (801) 387-2750 |
News Archive
New research out of the University of Minnesota identifies significant risk factors for suicidal behavior in youth being bullied, but also identifies protective factors for the same group of children.
A platform that simulates how the body defends itself: The T cells of the immune system decide whether to trigger an immune response against foreign substances.
Mersana Therapeutics, a platform-based cancer therapeutics company, announced today positive preclinical pharmacokinetic data for its lead development candidate, XMT-1001, which is currently in a Phase 1 clinical trial in patients with advanced solid tumors. The results were presented in a poster session at the AACR 101st Annual Meeting 2010 in Washington, DC, held April 17-21, 2010.
Geron Corporation today announced enrollment of the first patient in a randomized Phase 2 clinical trial of its telomerase inhibitor drug, imetelstat (GRN163L), as maintenance therapy following platinum-based induction therapy for patients with non-small cell lung cancer (NSCLC).
Genomic Health, Inc. today announced results from a study demonstrating the critical role of manual microdissection to remove all biopsy cavities from breast cancer specimens. Genomic Health's Oncotype DX is the only commercially available breast cancer test that employs manual microdissection following review by a board certified surgical pathologist with breast expertise to predict a patient's benefit from chemotherapy and risk of disease recurrence.
› Verified 6 days ago
Bruce E Thomas, MD Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 5957 Fashion Point Dr, Suite 101, Ogden, UT 84403 Phone: 801-475-5683 Fax: 801-475-9499 | |
Brent M Baranko, MD Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 4700 Harrison Blvd, Ogden, UT 84403 Phone: 801-475-3300 Fax: 801-475-3301 | |
Dr. Todd Ryan Grunander, M.D. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 4403 Harrison Blvd, Suite 2400, Ogden, UT 84403 Phone: 801-387-2750 | |
Brett Evan Richards, MD Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 4700 Harrison Blvd, Ogden, UT 84403 Phone: 801-475-3300 Fax: 801-475-3301 | |
Donald William Bryan, MD Orthopedic Surgery Medicare: Medicare Enrolled Practice Location: 4403 Harrison Blvd, Ste 2600, Ogden, UT 84403 Phone: 801-387-2600 Fax: 801-387-2625 | |
Damian Illing, MD Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 4700 Harrison Blvd, Ogden, UT 84403 Phone: 801-475-3300 Fax: 801-475-3301 |